Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML)

被引：13

作者：

Chomel, Jean-Claude ^{[1
,2
]}

Sorel, Nathalie ^{[2
]}

Bonnet, Marie-Laure ^{[2
]}

Bertrand, Angelina ^{[2
]}

Brizard, Francoise

Saulnier, Pierre-Jean ^{[3
]}

Roy, Lydia ^{[2
,3
]}

Guilhot, Francois ^{[2
,3
]}

Turhan, Ali G. ^{[2
]}

机构：

[1] CHU Poitiers, EA 3805, Serv Hematol & Oncol Biol, F-86021 Poitiers, France

[2] Univ Poitiers, EA 3805, Poitiers, France

[3] CHU Poitiers, Ctr Invest Clin, INSERM, U802, F-86021 Poitiers, France

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期

关键词：

CML; BCR-ABL; T315I mutation; Monitoring; KINASE DOMAIN MUTATIONS; BCR-ABL; FOLLOW-UP; IMATINIB; TRANSCRIPTS;

D O I：

10.1016/j.leukres.2008.08.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of chronic myeloid leukemia (CML). However, resistances are occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to TKIs commonly used in clinical practice. In the present study, we used an allele-specific quantitative-RT-PCR to perform a molecular follow-up of BCR-ABL transcripts harboring the T315I mutation. We retrospectively quantified BCR-ABL(315I) mRNA in five patients who acquired the T315I mutation. Our results highlight the relevance of allele-specific Q-RT-PCR experiments for the monitoring of mutated BCR-ABL transcripts and Suggest that the kinetics of emergence of T315I mutant mRNA is influenced by the stage of the disease and the presence of previous BCR-ABL kinase domain mutations. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：551 / 555

页数：5

共 9 条

[1] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors [J].

Cortes, Jorge ;

Jabbour, Elias ;

Kantarjian, Hagop ;

Yin, C. Cameron ;

Shan, Jianqin ;

O'Brien, Susan ;

Garcia-Manero, Guillermo ;

Giles, Francis ;

Breeden, Megan ;

Reeves, Nubia ;

Wierda, William G. ;

Jones, Dan .

BLOOD, 2007, 110 (12) :4005-4011

[2] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[3] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].

Gabert, J ;

Beillard, E ;

van der Velden, VHJ ;

Bi, W ;

Grimwade, D ;

Pallisgaard, N ;

Barbany, G ;

Cazzaniga, G ;

Cayuela, JM ;

Cavé, H ;

Pane, F ;

Aerts, JLE ;

De Micheli, D ;

Thirion, X ;

Pradel, V ;

González, M ;

Viehmann, S ;

Malec, M ;

Saglio, G ;

van Dongen, JJM .

LEUKEMIA, 2003, 17 (12) :2318-2357

[4] Selecting and deselecting imatinib-resistant clones:: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL [J].

Gruber, FXE ;

Lamark, T ;

Ånonli, A ;

Sovershaev, MA ;

Olsen, M ;

Gedde-Dahl, T ;

Hjort-Hansen, H ;

Skogen, B .

LEUKEMIA, 2005, 19 (12) :2159-2165

[5] Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients [J].

Hayette, S ;

Michallet, M ;

Baille, ML ;

Magaud, JP ;

Nicolini, FE .

LEUKEMIA RESEARCH, 2005, 29 (09) :1073-1077

[6] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

Jones, Dan ;

Breeden, Megan ;

Garcia-Manero, Guillermo ;

O'Brien, Susan ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Cortes, Jorge .

BLOOD, 2008, 112 (01) :53-55

[7]

JOHANSEN LE, 2006, THESIS I PHARM TROMS

[8] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia [J].

O'Hare, Thomas ;

Eide, Christopher A. ;

Deininger, Michael W. N. .

BLOOD, 2007, 110 (07) :2242-2249

[9] Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients [J].

Sorel, N ;

Chazelas, F ;

Brizard, A ;

Chomel, JC .

CLINICAL CHEMISTRY, 2005, 51 (07) :1263-1266

← 1 →